HIV trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in HIV. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month1 study across 1 company, in the next 180 days.
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BNTX | BioNTech SE | A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIVNCT07392372Parts A and B - Occurrence of at least one adverse event (AE) | Phase 1 | Recruiting | Nov 2026 | ≤ 102 d | 2026-08-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in HIV
most recently updated first339 studies match. Showing the first 100 of 339 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences | $177.9B | Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionNCT07473778observationalProportion of Participants with LEN PrEP Persistence at Week 52 | — | Recruiting | Drug: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet | HIV Infections | 3,000 | 2026-03-17 | Apr 2028 | ≤ 619 d | 2026-08-19 |
| GILD | Gilead Sciences | $177.9B | Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)NCT06101329Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN) at the End of Week 26 | Phase 2 | Active, not recruiting | Drug: Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Pre-Exposure Prophylaxis of HIV Infection | 253 | 2023-11-17 | 2026-07-22actual | — | 2026-08-17 |
| GILD | Gilead Sciences | $177.9B | Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyNCT07682961Proportion of Participants With HIV-1 ribonucleic acid (RNA) ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm. | Phase 3 | Recruiting | Drug: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine | HIV Infections | 590 | 2026-07-14 | Mar 2029 | ≤ 954 d | 2026-08-14 |
| GILD | Gilead Sciences | $177.9B | Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentNCT07708727Phase 2: Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm | Phase 2/3 | Recruiting | Drug: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF | HIV-1-infection | 700 | 2026-07-29 | Oct 2030 | ≤ 1,533 d | 2026-08-14 |
| GILD | Gilead Sciences | $177.9B | Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)NCT06101342Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN): LEN Plasma concentration at the End of the Dosing Interval (Week 26) | Phase 2 | Active, not recruiting | Drug: Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Pre-Exposure Prophylaxis of HIV Infection | 181 | 2023-12-13 | 2026-07-27actual | — | 2026-08-13 |
| BNTX | BioNTech SE | — | A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIVNCT07392372Parts A and B - Occurrence of at least one adverse event (AE) | Phase 1 | Recruiting | Drug: BNT351, Placebo, BNT351, Placebo | HIV -1 Infection | 67 | 2026-02-09 | Nov 2026 | ≤ 102 d | 2026-08-12 |
| GILD | Gilead Sciences | $177.9B | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated RegimenNCT05502341Phase 2: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm | Phase 2/3 | Active, not recruiting | Drug: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen | HIV-1-infection | 689 | 2022-08-16 | 2025-09-29actual | — | 2026-08-10 |
| GILD | Gilead Sciences | $177.9B | Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionNCT04994509results2025-06-19Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) | Phase 3 | Active, not recruiting | Drug: Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN), F/TAF, F/TDF, Placebo SC LEN, PTM Oral LEN, PTM F/TAF, PTM F/TDF | Pre-Exposure Prophylaxis of HIV Infection | 5,368 | 2021-08-30 | 2024-05-27actual | — | 2026-08-07 |
| GILD | Gilead Sciences | $177.9B | A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1NCT07645287Part A: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm | Phase 2 | Recruiting | Drug: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF | HIV-1-infection | 175 | 2026-06-15 | Aug 2027 | ≤ 376 d | 2026-08-06 |
| GILD | Gilead Sciences | $177.9B | Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensNCT07683000Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm. | Phase 3 | Recruiting | Drug: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, SBR | HIV-1-infection | 590 | 2026-07-14 | Mar 2029 | ≤ 954 d | 2026-07-30 |
| GILD | Gilead Sciences | $177.9B | Study of GS-0415 and How It Works in People With HIVNCT07719491Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) | Phase 1 | Not yet recruiting | Drug: GS-0415, GS-0415 Placebo | HIV -1 Infection | 112 | Jul 2026 | Aug 2029 | ≤ 1,107 d | 2026-07-22 |
| BNTX | BioNTech SE | — | A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIVNCT07698600Occurrence of at least one adverse event | Phase 1 | Not yet recruiting | Biological: BNT168 · Other: Placebo | HIV -1 Infection | 126 | Jul 2026 | Jan 2028 | ≤ 529 d | 2026-07-13 |
| GILD | Gilead Sciences | $177.9B | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVNCT07055451Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAs) Though Week 8 After Neonate Birth | Phase 1 | Active, not recruiting | Drug: B/F/TAF | HIV-1-infection | 16 | 2025-08-12 | Mar 2028 | ≤ 589 d | 2026-06-18 |
| GILD | Gilead Sciences | $177.9B | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyNCT06333808Proportion of Participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm | Phase 3 | Active, not recruiting | Drug: Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN | HIV-1-infection | 577 | 2024-03-25 | 2025-10-27actual | — | 2026-06-15 |
| GILD | Gilead Sciences | $177.9B | Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)NCT06513312Percentage of Participants with LEN and F/TDF Persistence through 52 Weeks | Phase 2 | Active, not recruiting | Drug: Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Pre-Exposure Prophylaxis of HIV Infection | 268 | 2024-10-07 | 2026-05-28actual | — | 2026-06-15 |
| GILD | Gilead Sciences | $177.9B | A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsNCT06337032Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the Study | Phase 4 | Recruiting | Drug: F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet), F/TAF (High Dose TOS), F/TAF (Low Dose TOS), F/TAF (Lowest Dose TOS), E/C/F/TAF, E/C/F/TAF (Low Dose), Cobicistat (High Dose), Cobicistat (Low Dose), Cobicistat (TOS), B/F/TAF (High Dose), B/F/TAF (Low Dose), B/F/TAF (High Dose TOS), B/F/TAF (Low Dose TOS), B/F/TAF (Lowest Dose TOS), 3rd ARV Agent, Nucleos(t)ide reverse transcriptase inhibitors (NRTI), ATV, DRV, Lopinavir Boosted with ritonavir (LPV/r) | HIV-1-infection | 350 | 2024-08-27 | Mar 2034 | ≤ 2,780 d | 2026-06-10 |
| GILD | Gilead Sciences | $177.9B | Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1NCT06532656PK Parameter: Cmax of BIC and LEN at Steady State | Phase 2/3 | Active, not recruiting | Drug: Lenacapavir, BIC/LEN FDC | HIV-1-infection | 75 | 2024-11-20 | Jul 2030 | ≤ 1,441 d | 2026-06-04 |
| GILD | Gilead Sciences | $177.9B | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1NCT06630299Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot Algorithm | Phase 3 | Active, not recruiting | Drug: ISL/LEN, Antiretroviral Combinations | HIV-1-Infection | 600 | 2024-10-08 | 2026-04-23actual | — | 2026-05-29 |
| GILD | Gilead Sciences | $177.9B | Study of GS-3242 in Participants With HIV-1; Substudy-05NCT07001319Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo Data | Phase 1 | Completed | Drug: GS-3242, BVY, Standard of Care | HIV-1-infection | 27 | 2025-05-29 | 2026-03-03actual | — | 2026-05-11 |
| GILD | Gilead Sciences | $177.9B | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1NCT06630286Proportion of Participants with HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the United States (US) Food and Drug Administration (FDA)-Defined Snapshot Algorithm | Phase 3 | Active, not recruiting | Drug: ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN | HIV-1-infection | 609 | 2024-10-09 | 2026-04-17actual | — | 2026-04-30 |
| GILD | Gilead Sciences | $177.9B | A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionNCT05729568results2025-07-15Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm | Phase 2 | Active, not recruiting | Drug: Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy | HIV-1 Infection | 83 | 2023-05-15 | 2024-07-02actual | — | 2026-04-27 |
| GILD | Gilead Sciences | $177.9B | Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and ChildrenNCT06749054Pharmacokinetic (PK) Parameter: Ctrough, W26 of Lenacapavir (LEN) | Phase 2 | Recruiting | Drug: Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR) | HIV-1-infection | 12 | 2025-03-26 | Mar 2027 | ≤ 223 d | 2026-04-24 |
| GILD | Gilead Sciences | $177.9B | Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVNCT02016924Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, TAF, and TFV | Phase 2/3 | Active, not recruiting | Drug: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS | Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | 133 | 2014-01-16 | 2025-06-13actual | — | 2026-04-21 |
| GILD | Gilead Sciences | $177.9B | Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedNCT06544733Phase 2: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot Algorithm | Phase 2/3 | Active, not recruiting | Drug: Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC | HIV-1-Infection | 675 | 2024-08-20 | Jan 2028 | ≤ 529 d | 2026-04-17 |
| GILD | Gilead Sciences | $177.9B | Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedNCT06613685Phase 2: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot Algorithm | Phase 2/3 | Terminatedsponsor's stated reason: Sponsor decision to terminate study. | Drug: lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide, lepetegravir/lenacapavir pacfosacil FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC | HIV-1-infection | 73 | 2024-10-21 | 2026-03-16actual | — | 2026-04-15 |
| GILD | Gilead Sciences | $177.9B | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1NCT02881320PK Parameter: AUCtau of Bictegravir | Phase 2/3 | Active, not recruiting | Drug: B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS) | HIV-1 Infection | 177 | 2016-09-21 | 2025-03-24actual | — | 2026-03-24 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug ResistanceNCT04150068results2021-10-20Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period | Phase 2/3 | Active, not recruiting | Drug: Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR) | HIV-1-infection | 72 | 2019-11-21 | 2020-10-05actual | — | 2026-03-13 |
| CYDY | CytoDyn, Inc. | $269M | Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionNCT02859961results2026-03-04Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure | Phase 2/3 | Completed | Drug: PRO 140 (350 mg), PRO 140 (525 mg), PRO 140 (700 mg) | HIV | 562 | 2016-12-07 | 2020-09-16actual | — | 2026-03-04 |
| GILD | Gilead Sciences | $177.9B | Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)NCT06104306results2026-02-11Percentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint) | Phase 4 | Completed | Drug: B/F/TAF | HIV-1-infection | 33 | 2023-12-13 | 2025-01-29actual | — | 2026-02-11 |
| GILD | Gilead Sciences | $177.9B | Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVNCT05052996results2025-01-14Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm | Phase 2 | Active, not recruiting | Drug: ISL, LEN, B/F/TAF, ISL/LEN FDC | HIV-1 Infection | 142 | 2021-10-05 | 2023-12-19actual | — | 2026-02-04 |
| GILD | Gilead Sciences | $177.9B | Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected WomenNCT05281510results2026-01-16Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: Vesatolimod · Biological: VRC07523LS, CAP256V2LS | HIV-1-infection | 20 | 2022-06-09 | 2025-01-16actual | — | 2026-01-16 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed ChildrenNCT01854775results2021-05-24Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1) | Phase 2/3 | Completed | Drug: E/C/F/TAF, E/C/F/TAF (Low Dose) | Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | 129 | 2013-05-06 | 2020-05-11actual | — | 2026-01-09 |
| GILD | Gilead Sciences | $177.9B | Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV InfectionNCT04925752results2025-09-17Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) | Phase 3 | Active, not recruiting | Drug: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only) | Pre-Exposure Prophylaxis of HIV Infection | 3,292 | 2021-06-28 | 2024-08-21actual | — | 2025-12-23 |
| CYDY | CytoDyn, Inc. | $269M | An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyNCT02990858results2025-11-12Mean Change in Viral Load (HIV-1 RNA Levels) at the Conclusion of Treatment Period | Phase 2/3 | Terminatedsponsor's stated reason: FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned. | Drug: PRO 140 | Human Immunodeficiency Virus (HIV) | 43 | 2016-11-03 | Jun 2022actual | — | 2025-11-12 |
| CYDY | CytoDyn, Inc. | $269M | An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 StudyNCT05271370results2025-10-30Long Term Clinical Safety of PRO 140 Monotherapy by Assessing the Number of Participants With Grade 2, 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale, and the Number of Participants With Treatment-emergent Serious Adverse Events. | Phase 2/3 | Terminatedsponsor's stated reason: FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned. | Drug: PRO 140 350, PRO 140 525, PRO 140 700 | HIV-1-infection | 56 | 2017-08-29 | 2022-06-20actual | — | 2025-10-30 |
| GILD | Gilead Sciences | $177.9B | Study of GS-1219 in Participants With HIV-1NCT07115368Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo Data | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to terminate study. | Drug: GS-1219, BVY, Standard of Care | HIV-1-infection | 4 | 2025-08-11 | 2025-09-19actual | — | 2025-10-21 |
| PFE | Pfizer | $155.3B | A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIVNCT05794191results2025-10-20observationalPCV13 Vaccine Effectiveness (VE) for First Event of Invasive Pneumococcal Disease (IPD): Overall Follow-up | — | Completed | Biological: Vaccine Administration | HIV, Pneumonia, Infections, Pneumococcal | 350,399 | 2023-03-22 | 2024-08-15actual | — | 2025-10-20 |
| CYDY | CytoDyn, Inc. | $269M | An Extension of Protocol PRO 140_CD01 StudyNCT02355184results2025-10-07Time to Virologic Failure After Initiating PRO 140 Monotherapy | Phase 2 | Terminatedsponsor's stated reason: FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned. | Drug: PRO 140 350mg weekly subcutaneous (SC) injection. | HIV, Human Immunodeficiency Virus | 20 | 2014-11-18 | Jun 2022actual | — | 2025-10-07 |
| CYDY | CytoDyn, Inc. | $269M | PRO 140 in Treatment-Experienced HIV-1 SubjectsNCT03902522results2025-09-16Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period | Phase 2/3 | Completed | Drug: PRO 140 | HIV-1-infection | 6 | 2018-06-25 | 2020-05-18actual | — | 2025-09-16 |
| GILD | Gilead Sciences | $177.9B | Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing RegimenNCT02285114results2021-01-12Pharmacokinetic (PK) Parameter (Cohort 1): AUCtau of Tenofovir Alafenamide (TAF) | Phase 2/3 | Completed | Drug: F/TAF, 3rd ARV agent, Boosted PIs | HIV-1 | 41 | 2015-01-20 | 2019-11-04actual | — | 2025-06-27 |
| GILD | Gilead Sciences | $177.9B | Study of Novel Antiretrovirals in Participants With HIV-1NCT05585307results2025-05-08Substudies 01, 02 and 03: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo Data | Phase 1 | Completed | Drug: Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03) | HIV-1-infection | 49 | 2022-10-26 | 2024-02-17actual | — | 2025-05-08 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionNCT04811040results2025-01-27Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) | Phase 1 | Completed | Drug: Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab, Zinlirvimab | HIV-1 Infection | 32 | 2021-04-08 | 2022-06-09actual | — | 2025-01-27 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVNCT04143594results2022-12-19Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm | Phase 2 | Completed | Drug: Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF | HIV-1-infection | 183 | 2019-11-22 | 2021-10-05actual | — | 2024-10-02 |
| ABVX | Abivax S.A. | — | ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor TreatmentNCT02735863results2024-09-19Number of Participants With Adverse Events | Phase 2 | Completed | Drug: ABX464, Placebo | HIV Infection | 30 | May 2016 | 2017-08-30actual | — | 2024-09-19 |
| GILD | Gilead Sciences | $177.9B | Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir AlafenamideNCT03580668observationalProportion of Participants with HIV-1 RNA Suppression (HIV RNA < 50 copies/mL) at 12 Months after initiating or switching to B/F/TAF | — | Completed | Drug: B/F/TAF | HIV-1-infection | 201 | 2018-11-13 | 2024-06-03actual | — | 2024-06-18 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersNCT03960645results2024-05-28Pharmacokinetic (PK) Parameter: AUCtau of Bictegravir (BIC) | Phase 1 | Completed | Drug: B/F/TAF | HIV-1-infection | 62 | 2019-06-28 | 2022-07-21actual | — | 2024-06-14 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)NCT04554966Incidence of Study Drug-Related Grade 3 or Higher Adverse Events (AEs) | Phase 1 | Completed | Drug: ABBV-382, ABBV-382, Placebo for ABBV-382 | Human Immunodeficiency Virus (HIV) | 54 | 2021-04-16 | 2023-08-14actual | — | 2024-03-04 |
| BMY | Bristol-Myers Squibb | $134.9B | Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCNCT01620944results2021-08-06Proportion of Participants With HIV-1 RNA < 40 c/mL at Week 48 | Phase 3 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: Atazanavir, Ritonavir, Lamivudine, Tenofovir/Emtricitabine | HIV | 3 | 2012-07-31 | 2013-01-22actual | — | 2024-01-10 |
| BMY | Bristol-Myers Squibb | $134.9B | Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneNCT01605084Proportion of subjects with Human immunodeficiency virus 1 (HIV-1) Ribonucleic Acid (RNA) < 50 c/mL | Phase 3 | Withdrawn | Drug: Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone | HIV | 0 | 2012-06-30 | 2014-08-31 | — | 2023-12-19 |
| CYDY | CytoDyn, Inc. | $269M | Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 InfectionNCT02175680results2023-04-14Time to Virologic Failure After Initiating PRO 140 Monotherapy. | Phase 2 | Completed | Drug: PRO 140 · Other: Historical data | HIV, Human Immunodeficiency Virus | 43 | 2014-04-16 | 2015-02-02actual | — | 2023-04-14 |
| ABVX | Abivax S.A. | — | A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive AdultsNCT02990325results2023-03-31Area Under the Curve (AUC) of ABX464 in Sera | Phase 1/2 | Completed | Drug: ABX464 150mg, ABX464 50mg, ABX464 50mg | HIV Infections, Health Volunteers | 36 | 2017-03-27 | 2018-12-27actual | — | 2023-03-31 |
| CYDY | CytoDyn, Inc. | $269M | Safety and Tolerability of PRO 140 in HIV Uninfected Male VolunteersNCT00110591results2023-03-14Safety and Tolerability of PRO 140 | Phase 1 | Completed | Drug: PRO 140 | HIV Infections | 20 | 2004-04-16 | 2005-11-07actual | — | 2023-03-14 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1NCT04223804Number of Participants with Study Drug-Related Adverse Events Grade 3 or Higher | Phase 1 | Completed | Drug: ABBV-181, Placebo | Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1 | 41 | 2020-01-30 | 2023-02-27actual | — | 2023-03-09 |
| CYDY | CytoDyn, Inc. | $269M | Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140NCT02483078results2022-11-03Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period | Phase 2/3 | Completed | Drug: PRO 140, Placebo, Optimized Background Regimen | HIV | 52 | Oct 2015 | Feb 2018actual | — | 2022-11-03 |
| ABBV | AbbVie | $457.5B | Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)NCT04799353Number of Participants Experiencing Study Drug-Related Grade 3 or Higher Adverse Events (AEs) | Phase 1 | Completed | Drug: Budigalimab, Placebo, Budigalimab, Placebo | Human Immunodeficiency Virus (HIV) | 33 | 2021-03-15 | 2022-10-11actual | — | 2022-10-17 |
| MGNX | MacroGenics | $261M | MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral TherapyNCT03570918results2022-09-02Number of Participants With Treatment-Emerging Adverse Events | Phase 1 | Completed | Biological: MGD014 | HIV-1-infection | 21 | 2018-09-25 | 2021-09-28actual | — | 2022-09-02 |
| GILD | Gilead Sciences | $177.9B | Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)NCT04009057observationalPercentage of Participants with HIV-1 RNA Suppression (HIV RNA < 50 copies/mL) at 12 Months after Initiating or Switching to B/F/TAF | — | Completed | Other: B/F/TAF | HIV-1-infection | 143 | 2019-07-09 | 2022-03-21actual | — | 2022-05-03 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT02607956results2018-06-06Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm | Phase 3 | Completed | Drug: DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo | HIV-1 Infection | 657 | 2015-11-11 | 2017-05-12actual | — | 2022-03-07 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT02607930results2018-07-23Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm | Phase 3 | Completed | Drug: ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo | HIV-1 Infection | 631 | 2015-11-13 | 2017-05-09actual | — | 2022-03-02 |
| GILD | Gilead Sciences | $177.9B | Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedNCT03110380results2019-11-20Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm | Phase 3 | Completed | Drug: B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo | HIV-1-infection | 567 | 2017-06-12 | 2018-12-04actual | — | 2022-01-11 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American ParticipantsNCT03631732results2020-08-27Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set | Phase 3 | Completed | Drug: B/F/TAF, NRTIs, Third Agent | HIV-1 Infection | 496 | 2018-08-28 | 2019-08-12actual | — | 2021-09-05 |
| GILD | Gilead Sciences | $177.9B | Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)NCT01906255observationalTreatment adherence, as measured by drug level, to the once-daily dosing regimen of FTC/TDF for PrEP | — | Completed | — | HIV | 10,577 | 2013-10-07 | 2021-04-27actual | — | 2021-09-01 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)NCT02738138results2018-05-09Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) | Phase 3 | Completed | Drug: ABT-493 coformulated with ABT-530 | Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics | 153 | 2016-05-17 | 2017-03-15actual | — | 2021-07-13 |
| ABBV | AbbVie | $457.5B | A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 CoinfectionNCT01939197results2017-11-17Percentage of Participants in GT1 Analysis Group 1 in Part 2 Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) | Phase 2/3 | Completed | Drug: ABT-450/r/ABT-267, ABT-333, ribavirin | Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics | 318 | 2013-08-30 | 2016-07-21actual | — | 2021-07-12 |
| ABBV | AbbVie | $457.5B | A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian FederationNCT04138199observationalPercentage of Participants Who Meet HIV-1- RNA Viral Load >50 Copies/mL, OR CD4+ T-Cell Counts < 200 Cells/mm^3 | — | Terminatedsponsor's stated reason: Strategic Considerations | — | HIV-1 Infection | 239 | 2019-11-01 | 2020-07-08actual | — | 2021-07-06 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected ControllersNCT03060447results2021-04-21Percentage of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Completed | Drug: Vesatolimod, Placebo, ART | HIV-1 Infection | 25 | 2017-05-09 | 2020-02-13actual | — | 2021-04-21 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsNCT01815736results2016-04-14Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 | Phase 3 | Completed | Drug: E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI | HIV, HIV Infections | 1,443 | 2013-03-27 | 2015-03-16actual | — | 2021-04-13 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected AdultsNCT03739866results2020-12-09Part A and Part B: Maximum Reduction From Day 1 (Baseline) Through Day 10 in Plasma HIV-1 RNA | Phase 1 | Completed | Drug: Lenacapavir, Placebo, B/F/TAF, TAF | HIV-1 Infection | 53 | 2018-11-26 | 2019-11-14actual | — | 2021-04-09 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant VirusNCT03472326results2021-01-05Part 1 Randomized Cohort: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 15 | Phase 2 | Terminatedsponsor's stated reason: GS-9131 did not meet the targeted antiviral response | Drug: GS-9131, BIC, TAF, ARV regimen, DRV, RTV | HIV-1-infection | 21 | 2018-04-03 | 2019-12-09actual | — | 2021-01-05 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected AdultsNCT02603107results2018-06-06Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm | Phase 3 | Completed | Drug: RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF | HIV-1 Infection | 578 | 2015-11-20 | 2017-05-15actual | — | 2020-12-29 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 YearsNCT03405935results2019-12-05Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the Food and Drug Administration (FDA)-Defined Snapshot Algorithm | Phase 3 | Completed | Drug: B/F/TAF | HIV-1 Infection | 86 | 2018-03-01 | 2018-11-20actual | — | 2020-12-01 |
| GILD | Gilead Sciences | $177.9B | Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically SuppressedNCT02603120results2018-07-23Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm | Phase 3 | Completed | Drug: ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo | HIV-1 Infection | 567 | 2015-11-11 | 2017-05-09actual | — | 2020-11-12 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected ParticipantsNCT02275065results2020-10-08Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA | Phase 1 | Completed | Drug: Bictegravir, Placebo | HIV-1 Infection | 23 | 2014-10-24 | 2015-01-23actual | — | 2020-11-09 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic HemodialysisNCT02600819results2018-10-16GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48 | Phase 3 | Completed | Drug: E/C/F/TAF, B/F/TAF | HIV-1 Infection | 55 | 2015-12-14 | 2017-09-29actual | — | 2020-11-05 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184INCT02616029results2019-11-04Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR) | Phase 3 | Completed | Drug: E/C/F/TAF | HIV-1 Infection | 66 | 2015-12-17 | 2018-10-11actual | — | 2020-07-23 |
| GILD | Gilead Sciences | $177.9B | A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)NCT01902472observationalSeroconversion rate among all subjects exposed to emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF) (Truvada®) for a PrEP indication | — | Completed | — | HIV | 172 | 2013-09-02 | 2017-10-30actual | — | 2020-07-14 |
| GILD | Gilead Sciences | $177.9B | Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsNCT02397694results2018-03-27Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm. | Phase 2 | Completed | Drug: BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF | HIV-1 Infection | 98 | 2015-03-23 | 2015-11-30actual | — | 2020-04-07 |
| GILD | Gilead Sciences | $177.9B | Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDFNCT02121795results2016-11-30Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis | Phase 3 | Completed | Drug: FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo | HIV-1 Infection | 668 | 2014-05-06 | 2015-08-12actual | — | 2020-03-12 |
| GILD | Gilead Sciences | $177.9B | Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsNCT02616783results2019-02-19Percent Change From Baseline to Week 48 in Spine BMD | Phase 3 | Completed | Drug: E/C/F/TAF, TDF, FTC, FTC/TDF, 3TC, Third agent | HIV-1 Infection | 167 | 2015-12-22 | 2018-02-21actual | — | 2020-03-04 |
| GILD | Gilead Sciences | $177.9B | Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenNCT02652624results2018-11-02Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm | Phase 3 | Completed | Drug: E/C/F/TAF, E/C/F/TDF, ATV, RTV, FTC/TDF, B/F/TAF | HIV-1 Infection | 472 | 2016-02-19 | 2017-10-09actual | — | 2020-03-04 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsNCT01797445results2016-01-08Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48 | Phase 3 | Completed | Drug: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo | HIV, HIV Infections | 872 | 2013-03-12 | 2014-09-19actual | — | 2020-03-02 |
| GILD | Gilead Sciences | $177.9B | Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal ImpairmentNCT01818596results2016-02-18Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24 | Phase 3 | Completed | Drug: E/C/F/TAF | HIV, HIV Infections | 252 | 2013-03-27 | 2014-07-31actual | — | 2020-03-02 |
| GILD | Gilead Sciences | $177.9B | Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed AdultsNCT02858401results2020-02-21Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) and Any Treatment-Emergent Adverse Events (AEs). | Phase 1 | Completed | Drug: Vesatolimod, Placebo, ARV regimen | HIV-1 Infection | 48 | 2015-01-29 | 2019-02-14actual | — | 2020-02-21 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected AdultsNCT02345226results2017-10-19Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-defined Snapshot Algorithm | Phase 3 | Completed | Drug: FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo | HIV-1 Infection | 881 | 2015-01-26 | 2016-06-29actual | — | 2020-01-02 |
| GILD | Gilead Sciences | $177.9B | Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)NCT02345252results2017-12-08Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm | Phase 3 | Completed | Drug: FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo | HIV-1 Infection | 632 | 2015-01-26 | 2016-06-22actual | — | 2020-01-02 |
| GILD | Gilead Sciences | $177.9B | Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver FibrosisNCT01707472results2019-10-09Percentage of Participants Experiencing Treatment-Emergent Adverse Events | Phase 2 | Completed | Biological: Simtuzumab | Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection | 18 | 2012-10-04 | 2014-10-17actual | — | 2019-11-05 |
| GILD | Gilead Sciences | $177.9B | Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TCNCT02469246results2018-06-11Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm | Phase 3 | Completed | Drug: F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent | HIV-1 Infection | 567 | 2015-06-29 | 2017-12-11actual | — | 2019-10-25 |
| GILD | Gilead Sciences | $177.9B | Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal FunctionNCT02400307results2019-10-11Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total) | Phase 1 | Completed | Drug: Bictegravir | HIV | 19 | 2015-04-17 | 2015-07-06actual | — | 2019-10-11 |
| GILD | Gilead Sciences | $177.9B | Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenNCT01705574results2016-03-10Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 of the Double-Blind Phase as Determined by the US FDA-Defined Snapshot Algorithm | Phase 3 | Completed | Drug: E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF | Acquired Immunodeficiency Syndrome, HIV Infections | 583 | 2012-10-24 | 2015-02-09actual | — | 2019-09-20 |
| ABBV | AbbVie | $457.5B | The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian FederationNCT02581202results2019-03-29observationalPercentage of Participants on Dual Therapy (LPV/r + 3TC) With Undetectable HIV-1 RNA Level at Week 48 | — | Completed | Drug: lopinavir/ritonavir, lamivudine | HIV-1 Infection | 216 | 2015-12-21 | 2017-05-27actual | — | 2019-06-06 |
| PFE | Pfizer | $155.3B | A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1NCT00823979results2014-03-14Percentage of Participants With Human Immunodeficiency Virus Type 1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 50 Copies/Milliliter (mL) at Week 24 | Phase 2 | Terminatedsponsor's stated reason: See termination reason in detailed description. | Drug: UK-453,061 Dose 1, UK-453,061 Dose 2, Etravirine | HIV-1 | 105 | 2009-03-25 | 2012-10-18actual | — | 2018-12-04 |
| GILD | Gilead Sciences | $177.9B | Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsNCT01497899results2016-01-08Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 | Phase 2 | Completed | Drug: E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo | Acquired Immunodeficiency Syndrome, HIV Infections | 279 | 2011-12-28 | 2012-10-17actual | — | 2018-11-19 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsNCT01780506results2016-01-08Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 | Phase 3 | Completed | Drug: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo | HIV, HIV Infections | 872 | 2012-12-26 | 2014-08-26actual | — | 2018-11-19 |
| GILD | Gilead Sciences | $177.9B | Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected AdolescentsNCT02276612results2018-02-22Incidence of Treatment-Emergent Serious Adverse Events | Phase 2/3 | Completed | Drug: E/C/F/TAF | HIV | 60 | 2014-12-03 | 2016-11-10actual | — | 2018-11-19 |
| GILD | Gilead Sciences | $177.9B | Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsNCT01967940results2017-06-12Part 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 10 | Phase 3 | Completed | Drug: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV | HIV, HIV Infections, Acquired Immunodeficiency Syndrome | 55 | 2013-10-25 | 2015-05-21actual | — | 2018-11-16 |
| GILD | Gilead Sciences | $177.9B | Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsNCT01968551results2016-11-01Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24 | Phase 3 | Completed | Drug: E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen | HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome | 158 | 2013-09-03 | 2015-07-21actual | — | 2018-11-16 |
| GILD | Gilead Sciences | $177.9B | Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected AdultsNCT02071082results2016-04-04Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL | Phase 3 | Completed | Drug: E/C/F/TAF | HIV, HBV | 79 | 2014-02-25 | 2015-01-23actual | — | 2018-11-16 |
| GILD | Gilead Sciences | $177.9B | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infectionNCT02073656results2016-10-21Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) | Phase 3 | Completed | Drug: LDV/SOF, RBV | Hepatitis C Virus, HIV | 335 | Feb 2014 | Nov 2014actual | — | 2018-11-16 |
| GILD | Gilead Sciences | $177.9B | Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsNCT02605954results2018-07-13Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24 | Phase 3 | Completed | Drug: E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent | HIV-1 Infection | 275 | 2015-11-18 | 2017-06-14actual | — | 2018-11-14 |
| GILD | Gilead Sciences | $177.9B | Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentNCT02707601results2018-10-09Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12) | Phase 3 | Completed | Drug: E/C/F/TAF, F/R/TAF, LDV/SOF | HIV-1 Infection, HCV Infection | 150 | 2016-04-01 | 2017-09-14actual | — | 2018-11-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How HIV is matched — 13 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- HIV Infections
- HIV
- HIV-1 Infection
- HIV-1-infection
- HIV Infection
- HIV-1
- Human Immunodeficiency Virus
- Human Immunodeficiency Virus (HIV)
- Pre-Exposure Prophylaxis of HIV Infection
- HIV -1 Infection
- HIV/AIDS
- Human Immunodeficiency Virus Infection
- Human Immunodeficiency Virus Type 1 (HIV-1)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “HIV” (a text search, wider than this page)